BSEP as a target for NAFLD treatment is of particular interest, as this transporter is the rate limiting step for bile acid efflux; thus, impacting this transporter may have a role in steatohepatitis. Here, ABCB11 is linked to metabolic dysfunction-associated steatotic liver disease.